14 recruiting, 8 completed, 6 unknown, 3 not yet recruiting. 18 Phase 1, 12 Phase 2, 10 Not applicable, 1 Early Phase 1.
Follow B-All: new trials by email Literature Review of B-All trials Research Report on B-All
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) TSLPR-CART, Cyclophosphamide, Fludarabine - B-All, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2026-10-28 | 2026-10-23 |
| A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... NGS testing - B-All, Acute Lymphoblastic Leukemia | Not applicable | Recruiting | National Cancer Institute (NCI) | 60 | 2026-10-28 | 2026-10-23 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-09-01 | 2026-08-11 |
| CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine - Acute Lymphoblastic Leukemia, B-All | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-06-16 | 2026-10-22 |
| Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy B-ALL, Hematologic Malignancy | Recruiting | St. Jude Children's Research Hospital | 100 | 2026-01-20 | 2026-06-18 | |
| KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia KSV01 Injection - B-ALL | Phase 1 | Recruiting | Zhejiang University | 30 | 2026-01-02 | 2026-07-17 |
| Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL) Nutrition Intervention, Exercise intervention - Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Not applicable | Recruiting | University of Chicago | 20 | 2025-05-12 | 2025-06-19 |
| A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia CD19 t-haNK - B-ALL, Leukemia | Phase 1 | Terminated | ImmunityBio, Inc. | 4 | 2025-04-11 | 2026-08-19 |
| JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia JY231 Injection - B-ALL | Not applicable | Not yet recruiting | He Huang | 24 | 2025-03-31 | 2025-03-30 |
| JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia JY231 Injection - B-ALL, B-NHL | Not applicable | Recruiting | Tongji Hospital | 20 | 2025-01-20 | 2025-07-08 |
| Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL S1904 CD19 CAR-T - B-ALL | Phase 2 | Recruiting | Hebei Senlang Biotechnology Inc., Ltd. | 59 | 2025-01-10 | 2025-11-24 |
| The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） - Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia) | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 90 | 2024-11-09 | 2025-04-04 |
| Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation Blinatumomab - B-ALL | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2024-11-01 | 2024-10-26 |
| The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation Blinatumomab - B-ALL | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2024-07-01 | 2024-07-16 |
| JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia JY231 Injection - B-NHL, B-ALL | Not applicable | Recruiting | Shenzhen Genocury Biotech Co., Ltd. | 20 | 2023-09-07 | 2024-11-07 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-16 |
| Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL UCAR-T Cells - B-cell Acute Lymphoblastic Leukemia, B-ALL | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 30 | 2022-12-05 | 2022-12-08 |
| Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL U-CAR-T Cells (LstCAR019) - B-cell Acute Lymphoblastic Leukemia, B-ALL | Phase 1 / Phase 2 | Withdrawn | Kunming Hope of Health Hospital | 2022-10-01 | 2022-11-30 | |
| Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL ThisCART19A - B-ALL | Phase 1 | Unknown | Zhejiang University | 16 | 2022-03-18 | 2022-04-28 |
| Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL ThisCART19A - B-ALL | Phase 1 | Completed | Zhejiang University | 10 | 2022-03-18 | 2026-02-17 |
Showing 20 of 34. Sign in to see all of them.
Burkitt Lymphoma (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Lymphoma (4) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Leukemia (2) · Leukemia, B-Cell (2) · Multiple Myeloma (2) · Philadelphia Chromosome (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphatic Diseases (1) · Lymphoma, Follicular (1)
Hemic and Lymphatic Diseases (21) · Neoplasms (21) · Neoplasms by Histologic Type (20) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (18) · Lymphoproliferative Disorders (18) · Hematologic Diseases (14) · Leukemia (10) · Leukemia, Lymphoid (10) · Lymphoma (10) · DNA Virus Infections (9) · Epstein-Barr Virus Infections (9) · Herpesviridae Infections (9) · Infections (9)
Cyclophosphamide (8) · fludarabine (7) · blinatumomab (5) · Cytarabine (2) · Etoposide (2) · Rituximab (2) · fludarabine phosphate (2) · Acetaminophen (1) · Antiemetics (1) · Antigens, CD19 (1) · Blood Component Removal (1) · Dexamethasone (1) · Diet Therapy (1) · Diphenhydramine (1) · Doxorubicin (1)
National Cancer Institute (NCI) (6) · Hebei Senlang Biotechnology Inc., Ltd. (4) · Zhejiang University (3) · Institute of Hematology & Blood Diseases Hospital, China (2) · Memorial Sloan Kettering Cancer Center (2) · St. Jude Children's Research Hospital (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Acerta Pharma BV (1) · Amgen Research (Munich) GmbH (1) · Cedars-Sinai Medical Center (1) · Chongqing Precision Biotech Co., Ltd (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · He Huang (1) · ImmunityBio, Inc. (1) · Kunming Hope of Health Hospital (1)
China (14) · United States (14) · Germany (1) · Italy (1) · Russia (1) · South Africa (1)
He Huang, Doctor (2) · Nirali N Shah, M.D. (2) · Peihua Lu, PhD&MD (2) · Sara K Silbert, M.D. (2) · Alexandra Dreyzin, M.D. (1) · Cheng Qian, PhD (1) · He Huang, MD (1) · Hongsheng Zhou (1) · Jae Park, MD (1) · Jia Wei, Doctor (1) · John W Glod, M.D. (1) · Li Li, MD (1) · Mark B Geyer, MD (1) · Matthew Frank, MD, PhD (1)
PMID 34687939, PMID 37486616, PMID 23753030, PMID 25385737, PMID 27209293, PMID 28533941, PMID 32286905, PMID 33512414, PMID 34309174, PMID 34889384, PMID 35605184, PMID 37295816, PMID 38376944, PMID 38996463, PMID 41411486, PMID 42248607
K08CA248968 (1)